Literature DB >> 11405284

Flurbiprofen enantiomers inhibit inducible nitric oxide synthase expression in RAW 264.7 macrophages.

B Hinz1, K Brune, T Rau, A Pahl.   

Abstract

PURPOSE: Using RAW 264.7 macrophages, the present study investigates the influence of optically pure enantiomers of the nonsteroidal anti-inflammatory drug flurbiprofen on lipopolysaccharide (LPS)-induced inducible nitric oxide synthase (iNOS) expression.
METHODS: iNOS and cyclooxygenase-2 (COX-2) mRNA levels were measured by quantitative real-time reverse-transcription polymerase chain reaction (RT-PCR). Concentrations of nitrite (index of cellular NO production) and prostaglandin E2 (index of COX-2 activity) in cell culture supernatants were determined by Griess assay and enzyme immunoassay, respectively.
RESULTS: R(-)- and S(+)-flurbiprofen decreased LPS-induced iNOS mRNA and nitrite levels in an equipotent and concentration-dependent manner. Suppression of iNOS mRNA expression by R(-)- and S(+)-flurbiprofen was gene-specific in that both substances failed to inhibit LPS-induced COX-2 mRNA expression. By contrast, flurbiprofen enantiomers suppressed LPS-induced prostaglandin E2 formation enantioselectively with S(+)-flurbiprofen being considerably more potent than its R(-)-antipode.
CONCLUSIONS: Our results show that R(-)- and S(+)-flurbiprofen, albeit differing in their potency as inhibitors of COX-2 activity, equipotently suppress iNOS expression. Because sustained high NO levels are associated with pain and tissue injury under various pathological conditions, a suppression of the inducible NO pathway may contribute to the pharmacological action of both R(-)- and S(+)-flurbiprofen.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11405284     DOI: 10.1023/a:1011020132140

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  29 in total

Review 1.  The mechanisms of action of nonsteroidal antiinflammatory drugs.

Authors:  S B Abramson; G Weissmann
Journal:  Arthritis Rheum       Date:  1989-01

Review 2.  Role of nitric oxide in the physiopathology of pain.

Authors:  M Anbar; B M Gratt
Journal:  J Pain Symptom Manage       Date:  1997-10       Impact factor: 3.612

3.  Nitric oxide inhibits inducible nitric oxide synthase mRNA expression in RAW 264.7 macrophages.

Authors:  B Hinz; K Brune; A Pahl
Journal:  Biochem Biophys Res Commun       Date:  2000-05-10       Impact factor: 3.575

4.  The anti-inflammatory drug sodium salicylate inhibits nitric oxide formation induced by interleukin-1beta at a translational step, but not at a transcriptional step, in hepatocytes.

Authors:  K Sakitani; H Kitade; K Inoue; Y Kamiyama; M Nishizawa; T Okumura; S Ito
Journal:  Hepatology       Date:  1997-02       Impact factor: 17.425

5.  Antiproliferative effects of the enantiomers of flurbiprofen.

Authors:  J D McCracken; W J Wechter; Y Liu; R L Chase; D Kantoci; E D Murray; D D Quiggle; Y Mineyama
Journal:  J Clin Pharmacol       Date:  1996-06       Impact factor: 3.126

6.  Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon gamma and lipopolysaccharide.

Authors:  C J Lowenstein; E W Alley; P Raval; A M Snowman; S H Snyder; S W Russell; W J Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

7.  Lipopolysaccharide-induced expression of prostaglandin H synthase-2 in alveolar macrophages is inhibited by dexamethasone but not by aspirin.

Authors:  M G O'Sullivan; E M Huggins; C E McCall
Journal:  Biochem Biophys Res Commun       Date:  1993-03-31       Impact factor: 3.575

8.  Inhibition of NF-kappa B by sodium salicylate and aspirin.

Authors:  E Kopp; S Ghosh
Journal:  Science       Date:  1994-08-12       Impact factor: 47.728

9.  Stereoselective disposition of flurbiprofen in healthy subjects following administration of the single enantiomers.

Authors:  G Geisslinger; J Lötsch; S Menzel; G Kobal; K Brune
Journal:  Br J Clin Pharmacol       Date:  1994-04       Impact factor: 4.335

10.  The effects of S- and R-flurbiprofen on the inflammation-evoked intraspinal release of immunoreactive substance P--a study with antibody microprobes.

Authors:  H G Schaible; V Neugebauer; G Geisslinger; U Beck
Journal:  Brain Res       Date:  1998-07-06       Impact factor: 3.252

View more
  5 in total

1.  Lack of enantiomeric influence on the brain cytoprotective effect of ibuprofen and flurbiprofen.

Authors:  J A López-Villodres; J P De La Cruz; J Muñoz-Marin; A Guerrero; J J Reyes; J A González-Correa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-06-29       Impact factor: 3.000

2.  Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.

Authors:  Isaac T Schiefer; Samer Abdul-Hay; Huali Wang; Michael Vanni; Zhihui Qin; Gregory R J Thatcher
Journal:  J Med Chem       Date:  2011-03-15       Impact factor: 7.446

3.  NO-flurbiprofen reduces amyloid-beta, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade.

Authors:  Samer O Abdul-Hay; Jia Luo; Rezene T Ashghodom; Gregory R J Thatcher
Journal:  J Neurochem       Date:  2009-08-21       Impact factor: 5.372

4.  Malarial pigment haemozoin, IFN-gamma, TNF-alpha, IL-1beta and LPS do not stimulate expression of inducible nitric oxide synthase and production of nitric oxide in immuno-purified human monocytes.

Authors:  Oleksii A Skorokhod; Evelin Schwarzer; Monica Ceretto; Paolo Arese
Journal:  Malar J       Date:  2007-06-02       Impact factor: 2.979

5.  Design of Targeted Flurbiprofen Biomimetic Nanoparticles for Management of Arthritis: In Vitro and In Vivo Appraisal.

Authors:  Hagar I Mohamed; Amal H El-Kamel; Ghada O Hammad; Lamia A Heikal
Journal:  Pharmaceutics       Date:  2022-01-07       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.